argenx SE at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and good afternoon. I'm James Gordon, JPMorgan European farmland biotech analyst. And today, kicking off the JPMorgan Healthcare Conference from the European side, I have the pleasure of introducing the argenx presentation and Q&A. So argenx CEO, Tim Van Hauwermeiren joining us, and it's an exciting time to talk to the company following FDA approval of Vyvgart for MG late last year. So really looking forward to the presentation. Thanks a lot. Over to you, Tim.
Thank you, James, and good morning and good afternoon, ladies and gentlemen. A very warm welcome to this argenx presentation. During the next 20 minutes, I will share our excitement about the year 2022, which is going to be an incredible year for us. We will see a great cadence of commercial Vyvgart launches. We will see numerous clinical catalysts and we will show how we continue to build a world-class product pipeline. We will discuss how
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
